Two phase I clinical trials, WU-KONG 1 and WU-KONG 2, are currently evaluating sunvozertinib for patients with metastatic NSCLC harboring EGFR or HER2 mutations. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.